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Genus Shigella is one of the important members of the family enterobacteriacae. There are numerous 
antigens in Shigella carrying by a 220 kb plasmid. Among them, IpaD is the key virulence factor of S. 
flexneri. Apart from having effectors function that is essential for host cell invasion and intracellular 
survival, this protein also controls the secretion and translocation of other effector proteins into 
eukaryotic host cells. In the present study, we have cloned and expressed the ipaD in E. coli. The 
ipaD gene was amplified by PCR. Prokaryote expression vector pET-28a(+)- ipaD was constructed, 
and used to transform E. coli BL21DE3 plySs. The expression of recombinant protein induced by 
IPTG was examined by SDS-PAGE. Western blot were used to determine immunoreactivity of IpaD-
His by a rabbit monoclonal antibodies against his-tag. SDS-PAGE demonstrated that the constructed 
prokaryotic expression efficiently produced IpaD at the 1 mmol/L of IPTG. IpaD protein was able to 
react with the rabbit monoclonal antibody against His-tag.  IpaD is essential for Shigella spp invasion. 
N-terminal region is most significant functional fragment of IpaD. Purification of IpaD from the wild 
type of Shigella is difficult furthermore profound study on a specific domain on the N-terminal of 
IpaD by using the wild type of purified IpaD is not feasible.  
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INTRODUCTION  
     Enterobacteriacae, are large groups of the 
enteric, non-spore forming bacteria which 
considered as normal inhabitants of intestine 
in both animals and human. E. coli, 
salmonella, klebsiella, proteus and 
enterobacter are some important genus in this 
family. Some strains such as E. coli are 
considering as normal inhabitants while some 
are normal flora of gastro-intestinal tract 
(GIT). A few genuses in the family, 
enterobacteriaceae such as Salmonella and 
Shigella are pathogen for human and animals 
[1]. Shigella dysentriae is one of the major 
causes of dysentery during last century, with a 
different mortality rate [1, 2]. The prevention 
of such diseases is mainly depending on the 
level of sanitation. No effective vaccination 
program has been proposed, so far. Few 
antigens of shigella have expressed which 
were potentially immunogenic in human. A 
large number of these antigens are carrying by 
a 220 kDa plasmid [3, 4]. A number of 
operons are located on the plasmid in which 
the entry region is playing a major role in the 
antigenicity of the microorganism [5]. ipaD is 
one of the operon harboring Ipa,a, b, c, and d 
[6]. Each operon is playing a role in the 
invasion of shigella to the M-cells with the 
clone [7]. IpaD is a 37 kDa with a dumbbell 
shape structure which exactly localizes to the 
tip of the type III secretion system needle of 
Shigella spp [8].  IpaD is necessary to invade 
the microorganism to host cells, carrying two 
main regions; N- and C-terminals in which the 
latter is a hydrophobic domain and not 
available in the environment. IpaD is fused to 
the C-terminal domain of a protein called 
MxiH, the main subunit of T3SS, thus, the 
protein residues of MxiH is cleaving a ligand 
for the C-terminal portion of IpaD [9, 8]. IpaD 
is interacting to the surrounding environment 
by its globular N-terminal. The key factor in 
the invasion of shigella to host epithelial cells 
is depending on the function of IpaD [7, 8]. 
Bile salts are also necessary to induce the 
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invasive potential of the bacterium [10]. In 
fact, the reaction between bile salts especially 
deoxycolate with IpaD may recruitment and 
employment of other proteins to locate on cell 
membrane of the bacterium [8, 11]. The 
condition permits the bacterium to attach and 
invade the host cells [8, 12]. Laboratory 
techniques and statistical analysis of previous 
data are indicating that deoxycolate can 
directly attach to a specific region on the N-
terminal portion of IpaD, between MixH and 
IpaD. Any interaction in the function of this 
region may limit the function of IpaD and thus 
block the attachment process and/or invasion 
of the bacterium to the target cells [8, 11]. 
Previous researches have shown that the 
antibody that detects the N-terminal of IpaD, 
can stop the ability of the microorganism in 
making pores in red blood cells (RBC) [8]. 
However, further researches have shown that 
anti- IpaD antibody may inhibit the entry of 
shigella into its host cells. Recent work on 
producing an effective vaccine against shigella 
is based on using IpaD and its functional 
derivatives was also successful [13]. 
Therefore, IpaD could be considered as 
potential candidate and thus, some more work 
on the antigenicity of IpaD are seems to be 
Recruitment. Cloning and expression of the 
ipaD and its derivatives are necessary to find 
more about the antigenicity of such 
compounds. In the present study, we have 
tried to clone and express the N-terminal 
portion of the IpaD. 
 
MATERIALS AND METHODS 
 
Enzymes, Vectors and Bacterial strains 
     Pfu DNA polymerase (2.5U/μl, Fermentas, 
Lithuania), Enzymes HindIII and EcoRI  
(Fermentas, Lithuania.), IPTG (Vivantis, 
Malesia), Vector pET-28a(+) (Novagen USA), 
Vector pGEM-T (Promega, USA), S. 
dysenteria, was  prepared from Milad hospital 
and confirmed by biochemical and serological 
tests. the genomic DNA of shigella dysenteria 
was Extracted and used as the templet in PCR 
experiment. E. coli DH5α and E. coli 
BL21DE3 plysS were used for cloning and 
expression experiments respectively. Plasmid 
pGEM-T Vector and pET-28a(+) were used as 
cloning and expression vectors respectively. 
 
Amplification of N-terminal section of ipaD 
gene 
     Genomic DNA was extracted by a routine 
CTAB NaCl method [14]. The DNA fragment 
coding for N-termial region of ipaD gene, 
with accession number NC_007607.1, was 
amplified by using 2 primers. These primers 
which were designed by oligo software were  
IpaDF (5 َT CAT GAA TTC AGA ACA ACA 
AAT CAG 3)َ as a forward primer with an 
endonuclease site of EcoR I and IpaDR (5 َ T 
CTT AAG CTT TTA AGT ATA TGA ACT 
AAC G 3' ) as reverse primer with an 
endonuclease site of HindIII. Synthesis of 
those primers was performed by Cinaclon Bio-
tech Company. Amplification was made in a 
total volume of 50 μl of reaction mixture 
containing 1µl of genomic DNA( 0.5µg/µl) , 5 
μl of 10× Pfu buffer with MgSo4, 5 μl dNTP 
Mix(2mM each), 2 µl of each primer (10 
pmol) and 0.25 µl of Pfu DNA polymerase 
(2.5 unit/µl). By adding double-distilled water, 
the reaction mixture reached the Final volume 
50 µl. A total of 32 cycles was performed with 
the first denaturation at 95 °C for 5 min, then 
30 cycles at 95 °C for 30 second, 57 °C for 30 
second and 72 °C for 30 second, and the final 
extension at 72 °C for 5 min. The amplified 
products were analyzed by electrophoresis 
with a 1% agarose gel followed by ethidium 
bromide staining and UV-transilluminator 
visualization. 
 
Cloning, subcloning and sequencing 
     The PCR products of N-terminus region of 
ipaD were trailed with dATP, ligated with 
pGEM-T vector and transformed into E. coli 
DH5α. Ampicillin selection and some control 
tests ensured the presence of the recombinant 
plasmid. In order to subcloning, Fragments of 
EcoRI and HindIII-digested ipaD were 
inserted into the EcoRI/HindIII site of 
expression vector pET-28a(+), through 
enzyme digestion and ligation reactions. Then 
the recombinant plasmid pET-28a(+)-ipaD 
was confirmed by PCR and restriction enzyme 
digestion. Recombinant pET-28a(+)-ipaD was 
amplified in competent E. coli DH5α and then 
extracted by Alkaline lysis method [14]. The 
resulting plasmid pET-28a(+)-ipaD was 
Transformed  into competent final host E. coli 
BL21DE3 plysS  and kanamycin resistance 
was used for selection [14]. A recombinant 
plasmid was prepared and identified by 
restriction enzymes. In order to sequence of 
inserted fragment, 20 µl of purified 
recombinant plasmid was sequenced by Koser 
Bio-tech Company.  
 
Expression and identification of the fusion 
protein 
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     The N-terminal ipaD expression system 
pET-28a(+)-ipaD   BL21DE3 was cultured in 
LB medium at 37 °C. After the OD of bacteria 
reached to 0.6, it induced by isopropylthio-β-
D-galactoside (IPTG) at final concentration of 
1 mmol/L. The precipitate and incubated for 
5h. The bacteria were collected by 
centrifugation and the cell pellet was broken 
by B Buffer (NaH2PO4:13/8gr, Tris.HCl:1/2gr 
,urea 480/5gr, add DDW to 1liter,adjust pH in 
8). The molecular weight of IpaD fusion 
protein was identified by sodium dodecyl 




      Immunoreactivity of IpaD fusion protein 
was determined by Western blot. For Western 
blotting, proteins were transferred to 
nitrocellulose membrane and incubated with 
the rabbit antiserum against Histidin and HRP-
labeling sheep anti-rabbit IgG as the first and 




Construction of recombinant pET-28a(+)-
ipaD 
     The PCR product amplified from genomic 
DNA of shigella is shown in figure 1. The 
344-bp expected fragment amplified by PCR 
contained a gene ipaD. The 344-bp PCR 
product was cloned into pGEM-T vector at 
first step. The recombinant pGEM-T-ipaD 
vector digested with EcoRI and HindIII 
enzymes and ipaD fragments ligated into the 
corresponding sites of pET-28a(+). The 
recombinant plasmids pET-28a(+)-ipaD were 
digested by EcoRI and HindIII and analyzed 
































Expression of recombinant fusion protein 
     The recombinant pET-28a(+)-ipaD was 
transformed into E. coli BL21DE3 strains and 
the fusion protein was expressed. The 1 
mmol/L of IPTG was able to efficiently induce 
expression of IpaD fusion protein with a 
predicted molecular mass of 16.7 kDa is 
shown in figure 3. A culture of recombinant E. 
coli BL21DE3 plysS that wasn’t induced by 
IPTG used as a negative control. 
 




Figure 1. The target fragment of N-terminal of ipaD 
gene amplified from Shigella dysenteriae.  
Lane 1: The target amplification of ipaD gene (S. 
dysenteriae) 
Lane 2: 100 bp DNA size marker. (#SM0623 purchased 
from fermentas co.) 
 
Figure 2. Agarose gel electrophoresis analysis of 
recombinant pET-28a(+)-ipaD 
Lane1: Double digests of recombinant pET-28a(+)-ipaD 
with EcoRI and HindIII 
Lane2: Recombinant pET-28a(+)-ipaD without digestion  
Lane3: 100bp DNA size marker (#SM0623 purchased 
from fermentas co.) 
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antibody against Histidine tag. 
     Expression of the N-terminal region of 
IpaD was investigated in E. coli. For this 
reason, an antibody against the Histidine tag 
was employed. The expression of the 
recombinant protein was then confirmed by 
appearing a proper band control is shown in 














     The main agent of shigellosis is S. 
dysentriae, which is a gram negative 
pathogenic bacterium characterized by its 
invasion to the epithelial cells of large 
intestine. Attachment of the microorganism to 
the host cells may induce an explosive 
secretion of proteins via the type three 
secretion system (TTSS) of the bacterium. 
Shigella is transmitted by the fecal-oral route, 
typically via contaminated water, and is spread 
efficiently due to an unusually low 50% 
infective dose [7]. After ingestion, acid-
tolerant S. dysenteriae passes through the 
stomach to the colonic mucosa, by transcytosis 
through M cells and encounters resident 
macrophages [15]. There, the shigellae enter 
macrophages and efficiently induce apoptosis, 
leading to the eventual release of the pathogen 
on the basal side of the colonic epithelium 
[16]. The Shigellae then invade these 
epithelial cells by inducing major cytoskeletal 
rearrangements [17]. The Shigella invasive 
genes have located on a 31-kb region of its 
large virulence plasmid which includes the 
genes for the type III secretion system (TTSS) 
[18]. The first group of proteins in which are 
excreted are; IpaD, IpaB and IpaC. The IpaD 
is essential component to invade the host cells. 
Antibodies are able to recognize the surface 
Figure 4. Western blotting analysis of expressed pET-28a-
ipaD products. 
Lane 1: Induced recombinant bacterial cells  
Lane 2: Induced recombinant purified protein by nickel 
column 
Lane 3: Protein size marker (cat No:#SM0671 purchased 
from fermentas co.) 





Figure 3. Expression of IpaD protein in pET-28a(+)-ipaD-
BL21DE3 plysS 
Lane 1: Negative control (Non-induced recombinant bacterial 
cells) 
Lane 2: Protein size marker (cat No:#sm0671 purchased from 
fermentas co.) 
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epitopes of IpaD. In the present study, the 
antigenic properties of IpaD was investigated 
by calculative and laboratory techniques. The 
overall surface available epitopes of the IpaD 
are surrounded within the first 180 amino-
acids composition of the protein, whereas, the 
carboxyl region in the surface of Shigella is 
not available. Even though, hydrophilic areas 
are present in the carboxyl side, recent studies 
on the serum of animals have shown that the 
production of antibodies against the C-
terminal is considerably lower than the N-
terminal region [19]. Purification of IpaD from 
the wild type of Shigella has previously 
explained. However, the technique is difficult, 
firstly because the microorganism produces 
the IpaD protein in low level. The second 
difficulty in the purification of IpaD is 
referring to find it among the plenty of 
proteins which need expensive and 
sophisticated biochemical techniques [20]. 
However, a profound study on a specific 
domain  on the N-terminal of IpaD by using 
the wild type of purified IpaD is not feasible; 
furthermore, the risks of working with the 
wild type of Shigella and also high costs 
experiments are making them to be 
impractical. 
     The microorganism produces the IpaD 
protein in low level and purification of IpaD 
among the plenty of proteins is very difficult. 
one of the suitable method for producing of 
high level of protein is utilizing of 
recombinant method. Using of this method 
also endow the ability of studying on a 
specific region of antigen like IpaD. Although 
purification of IpaD from wild type bacterium 
is difficult but it can proposed as a vaccine 
candidate for shigellosis.   
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